Similar articles

• Ranolazine in patients with incomplete revascularisation after percutaneous coronary intervention (RIVER-PCI): a multicentre, randomised, double-blind, placebo-controlled trial.

  Weisz G, Généreux P, Iñiguez A, Zurakowski A, Shechter M, Alexander KP, Dressler O, Osmukhina A, James S, Ohman EM, Ben-Yehuda O, Farzaneh-Far R, Stone GW; RIVER-PCI investigators. Weisz G, et al. Lancet. 2016 Jan 9;387(10014):136-45. doi: 10.1016/S0140-6736(15)00459-6. Epub 2015 Oct 22. Lancet. 2016. PMID: 26474810 Clinical Trial.
• Ranolazine following percutaneous coronary intervention: For whom? For what?

  Redfors B, Généreux P. Redfors B, et al. Expert Rev Cardiovasc Ther. 2016;14(5):541-3. doi: 10.1586/14779072.2016.1150176. Epub 2016 Feb 27. Expert Rev Cardiovasc Ther. 2016. PMID: 26840661 No abstract available.
• [The RIVER-PCI study].

  Ferlini M, Borghesi M, Musumeci G. Ferlini M, et al. G Ital Cardiol (Rome). 2017 Oct;18(10):677-681. doi: 10.1714/2790.28256. G Ital Cardiol (Rome). 2017. PMID: 29105681 Clinical Trial. Italian. No abstract available.
• New Anti-Anginal Drugs: Ranolazine.

  Cavallino C, Facchini M, Veia A, Bacchni S, Rosso R, Rognoni A, Rametta F, Lupi A, Bongo AS. Cavallino C, et al. Cardiovasc Hematol Agents Med Chem. 2015;13(1):14-20. doi: 10.2174/1871525713666141219112841. Cardiovasc Hematol Agents Med Chem. 2015. PMID: 25544118 Review.
• Role of Ranolazine in cardiovascular disease and diabetes: Exploring beyond angina.

  Banerjee K, Ghosh RK, Kamatam S, Banerjee A, Gupta A. Banerjee K, et al. Int J Cardiol. 2017 Jan 15;227:556-564. doi: 10.1016/j.ijcard.2016.10.102. Epub 2016 Nov 2. Int J Cardiol. 2017. PMID: 27838121 Review.